VMD Stock Forecast: Viemed Healthcare, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Viemed Healthcare, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 99 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Viemed Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Revisions (49): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
VMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Freedom Broker | Maintains | Hold | $11 → $10 |
| 24 Aug 2026 | Barrington Research | Initiates | Outperform | — |
| 6 Aug 2026 | Freedom Broker | Downgrade | Hold | $11 |
| 3 Nov 2021 | RBC Capital | Maintains | Outperform | $13 → $9.00 |
| 5 Mar 2021 | RBC Capital | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VMD.
This page is one stock. Monday covers all of them.
VMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
VMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Viemed Healthcare, Inc. returned +34.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
VMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 22.4×
- Price / sales
- 1.0×
- Price / book
- 2.2×
- EV / EBITDA
- 5.8×
Cheaper than 40% of US stocks
Cheaper than 65% of US stocks
Cheaper than 41% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 32.0%
- Gross margin
- 57.7%
- Operating margin
- 8.4%
- Net margin
- 5.0%
Higher than 67% of US stocks
Higher than 71% of US stocks
Higher than 61% of US stocks
Higher than 57% of US stocks
- Return on equity
- 11.2%
- Return on assets
- 7.9%
- Dividend yield
- —
Higher than 65% of US stocks
Higher than 87% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Viemed Healthcare, Inc. has a market value of $322.8M and an enterprise value of $324.4M.
Revenue in the twelve months to 30 June 2026: $301.6M. The latest quarter grew 23.9% year on year.
Net income over the same four quarters: $15.0M, a 5.0% net margin.
Diluted earnings per share, trailing twelve months: $0.36.
Free cash flow in the twelve months to 30 June 2026: $29.2M.
Viemed Healthcare, Inc. spent $20.5M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 22.4×; forward P/E: 21.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Viemed Healthcare, Inc. employs 1,490 people — $202K of revenue per employee.
Data provided by Twelve Data
VMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at VMD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Viemed Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about VMD
What is the VMD stock price forecast for 2026-2027?
The median 12-month analyst price target for Viemed Healthcare, Inc. is $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VMD stock a buy right now?
Of the 2 analysts covering Viemed Healthcare, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viemed Healthcare, Inc. 99 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VMD?
As at 21 Nov 2026, Viemed Healthcare, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
Will VMD stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $12, and Ticker Nerd's factor model ranks Viemed Healthcare, Inc. 99 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VMD stock forecast for 2030?
No analyst covering Viemed Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.
How has VMD stock performed over the past year?
Viemed Healthcare, Inc. returned +34.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Viemed Healthcare, Inc. do?
Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings.
About Viemed Healthcare, Inc.
Viemed Healthcare, Inc. is a healthcare company that provides home medical equipment and post-acute respiratory care services in the United States. The company focuses on in-home treatment for patients with respiratory conditions, offering equipment, therapy support, and clinical services designed to help manage complex breathing disorders outside traditional hospital settings. Its current product and service portfolio includes non-invasive ventilation, oxygen equipment, sleep apnea testing and treatment, positive airway pressure therapy, respiratory disease management, and related supplies and support services. Viemed also provides complementary clinical and staffing services that support patient care in the home. The company serves patients nationwide and operates within the broader home healthcare and durable medical equipment markets, where it plays a specialized role in respiratory-focused in-home care.
CEO Mr. Casey Hoyt · 1,490 employees · United States · https://www.viemed.com